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We report a rare case of multiple myeloma with biclonal gammopathy (IgG kappa and IgA lambda type) in a 58-year-old man with 
prostate cancer who presented with lower back pain. Through computed tomography (CT) imaging, an osteolytic lesion at the L3 
vertebra and an enhancing lesion of the prostate gland with multiple lymphadenopathies were found. In the whole body positron 
emission tomography-computed tomography (PET-CT), an additional osteoblastic bone lesion was found in the left ischial bone. A 
prostate biopsy was performed, and adenocarcinoma was confirmed. Decompression surgery of the L3 vertebra was conducted, 
and the pathologic result indicated that the lesion was a plasma cell neoplasm. Immunofixation electrophoresis showed the pres-
ence of biclonal gammopathy (IgG kappa and IgA lambda). Bone marrow plasma cells (CD138 positive cells) comprised 7.2% of 
nucleated cells and showed kappa positivity. We started radiation therapy for the L3 vertebra lesion, with a total dose of 3,940 cGy, 
and androgen deprivation therapy as treatment for the prostate cancer. 
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INTRODUCTION
Multiple myeloma is a malignant disease of plasma cells 
that manifests as disease in the bone marrow, monoclonal 
protein in the blood and/or urine, and evidence of end or-
gan damage that can be attributed to the underlying plasma 
cell proliferative disorder [1]. Biclonal gammopathies are a 
group of disorders characterized by the production of 2 dis-
tinct monoclonal proteins. The presence of 2 monoclonal 
proteins may be because of the proliferation of 2 clones of 
plasma cells, each producing an unrelated monoclonal im-
munoglobulin, or it may result from the production of 2 
monoclonal proteins by a single clone of plasma cells [2]. 
Although there are some reports of synchronous occurrence 
of multiple myeloma and prostate cancer [3, 4], there are no 
reports of multiple myeloma with biclonal gammopathy ac-
companied by prostate cancer. Here, we report a rare case 
of multiple myeloma with biclonal gammopathy accompa-
nied by prostate cancer, which was treated successfully by 
androgen deprivation therapy for the prostate cancer and 
surgery combined with radiation therapy for the plasma cell 
neoplasm.
CASE REPORT
A 58-yr-old man visited the orthopedic surgery depart-
ment of a local clinic in January 2008, with a 10-day history 
of lower back pain and tingling sensation of the left gluteal 
region and thigh. At the local clinic, spinal magnetic reso-
nance imaging (MRI) was performed, and the clinician sus-
pected a bone tumor. The patient was then transferred to 
the Hematology/Oncology Department of Eulji University 
Hospital for further evaluation. The patient had no history 
of trauma. In addition to the back pain and tingling sensa-
tion of the gluteal region and thigh, the patient complained 
of urinary symptoms, including hesitancy, mild voiding dif-
ficulties, and residual urine sensation. A physical examina-
tion revealed lower back tenderness, but other findings were 
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The patient’s peripheral white blood cell count was 3,990/μL, 
hemoglobin and platelet counts were 12.5 g/dL and 225,000/
μL, respectively. Blood chemistry tests yielded the following 
results: total protein, 7.2 g/dL; albumin, 4.3 g/dL; AST, 25 
U/L; ALT, 43 U/L; alkaline phosphatase, 88 U/L; total bili-
rubin, 0.6 mg/dL; calcium, 9.1 mg/dL; phosphorus, 4.3 mg/
dL; blood urea nitrogen (BUN), 21 mg/dL; and creatinine, 
1.0 mg/dL. Blood electrolyte analysis yielded the following 
results:sodium, 139 mmol/L; potassium, 4.1 mmol/L; and 
chloride, 103 mmol/L. Tumor markers detected included 
alpha-fetoprotein (AFP), 8.1 ng/mL; carcinoembryonic an-
tigen (CEA), 1.49 ng/mL; carbohydrate antigen 19-9 (CA 19-
9), 21.29 IU/mL; and prostate specific antigen (PSA), 62.40 
ng/mL.
Spinal MRI revealed an osteolytic extension lesion with 
cortical pinning on the left half of the L3 vertebra, including 
the left transverse process (Fig. 1). Abdominal and chest 
computed tomography (CT) revealed an enhancing lesion 
of the prostate gland. Multiple metastatic lymphadenopa-
thies were discovered in the paraaortic, aortocaval, and com-
mon iliac lymph nodes as well as in the left pelvic wall. A 
whole body positron emission tomography-computed to-
mography (PET-CT) was performed (Fig. 2A). In the pros-
tate gland, the standardized uptake value (SUV) was 3.45 
for the lesion showing fructose-1,6-bisphosphate (FDP) up-
take; maximum SUV was 4.57 for the lesion showing FDP 
uptake in the L3 vertebral body and transverse process; and 
SUV was 2.87 for the lesion showing FDP uptake in the left 
iliac bone. Multiple lesions showing FDP uptake were ob-
served in the paraaortic, aortocaval, prevertebral, and left 
common iliac regions, with an SUV range of 2.27-4.1.
A prostate biopsy was performed under transrectal ultra-
sonographic guidance, and adenocarcinoma was confirmed 
in the pathologic review (Fig. 3A). Because of the patient’s 
severe back pain, decompression surgery of the L3 vertebra 
and a biopsy of the lesion were performed. The biopsy re-
sults characterized the lesion as a plasma cell neoplasm (Fig. 
3B). 
Blood analysis yielded the following values: serum beta 2 
microglobulin, 0.17 mg/dL; serum IgG, 1,436.6 mg/dL (ref-
erence interval: 870-1,700 mg/dL); IgA, 445.9 mg/dL (refer-
ence interval: 110-410 mg/dL); and IgM, 123.62 mg/dL (re-
ference interval: 35-220 mg/dL). Serum protein electropho-
resis showed an M-peak in the gamma fraction (serum M-
protein was 217 mg/dL), and immunofixation electropho-
resis revealed the presence of biclonal gammopathy (IgG 
kappa and IgA lambda). Urine immunofixation electropho-
resis showed a dark band for kappa antisera (Fig. 4). In the 
24-hr urine samples, the total protein was 151.2 mg/day 
and urine protein electrophoresis indicated tubular protein-
uria with Bence-Jones proteinuria. Immunohistochemical 
staining of the bone marrow was performed with CD138, 
kappa, and lambda, and the bone marrow was positive for 
CD138 and kappa staining. Bone marrow plasma cells (CD-
138 positive cells) comprised 7.2% of nucleated cells (Fig. 5). 
Plain radiographic examination of the whole body did not 
show any abnormalities other than that in the L3 vertebra. 
Finally, we diagnosed the patient with multiple myeloma 
showing biclonal gammopathy accompanied by stage IV 
prostate cancer (due to an ischial bone metastatic lesion).
Fig. 1. Spinal magnetic resonance imaging (MRI). A plasma cell neoplasm compressing the spinal cord is seen in the L3 vertebral body. (A) Sagittal view. (B) Trans-
verse view.
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Fig. 2. PET-CT performed at diagnosis and follow-up at 27 months. (A) At diagnosis, increased FDP uptake was seen in the L3 vertebral body, the prostate gland, 
and ischial bone. Further, hypermetabolic activity was seen in the paraaortic, aortocaval, prevertebral, and left common iliac lymph nodes. These findings may 
suggest metastatic lymphadenopathies. Increased FDP uptake was seen in the ischial bone. (B) Follow-up PET-CT after 27 months. At the end of the follow-up, an 
improvement in intra-abdominal lymphadenopathies and disappearance of the hypermetabolic lesion in the prostate gland and ischial bone were observed.
Abbreviations: PET-CT, positron emission tomography-computed tomography; FDP, fructose-1,6-bisphosphate. 
A B
Fig. 3. (A) Prostate gland biopsy. It shows cancer infiltration of individual cells. It may suggest the presence of a gland-forming adenocarcinoma (Hematoxylin & 
Eosin, ×200). (B) L3 vertebral body biopsy. Some plasma cells show increased nuclear/cytoplasmic ratios, and they contain an eccentric nucleus and a peri-nu-
clear halo. Some other cells have double nuclei (Hematoxylin & Eosin, ×400).
A B
We started radiation therapy on the L3 vertebra plasma 
cell neoplasm, with a total dose of 3,940 cGy, and androgen 
deprivation therapy with bicalutamide (50 mg/day) and go-
serelin (3.78 mg/month) as well as bisphosphonate (90 mg/ 
month) for prostate cancer treatment. After 27 months, we 
performed a whole-body PET-CT (Fig. 2B), which revealed 
no abnormal FDP uptake in the intra-abdominal lymph no-
des, prostate gland, and left iliac bone. Left vertebral body 
SUV uptake increased to SUV 3.10, but this change was con-
sidered as a post-radiotherapy change. PSA decreased to 
0.05 ng/mL, which was within the reference interval. Fol-
low-up serum protein electrophoresis revealed an M-peak 288     www.kjlm.org
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Fig. 4. (A) Protein electrophoresis. An M-peak is seen in the gamma fraction. (B) Serum immunofixation electrophoresis. It shows biclonal gammopathy of IgG 
kappa type and IgA lambda type. (C) Urine immunofixation electrophoresis. It shows a dark band for kappa antisera.
(serum M-protein was 260 mg/dL) and immunofixation 
electrophoresis revealed the presence of biclonal gammopa-
thy (IgG kappa and IgA lambda). The patient was adminis-
tered 10 mg amitriptyline to control the neurologic pain in 
the left thigh and gluteal region. Nineteen months later, the 
neurologic pain disappeared, and medication was discon-
tinued. The patient is doing well without evidence of tumor 
recurrence at 37 months after the initial diagnosis and treat-
ment.
DISCUSSION
We reported a rare case of multiple myeloma with biclo-
nality (IgG kappa and IgA lambda monoclonal proteins) in 
a 58-year-old man diagnosed with prostate cancer. The in-
cidence of the simultaneous occurrence of prostate cancer 
and hematolymphoid malignancies has been reported to be 
1.2% [5]. Biclonal gammopathy accounts for approximately 
1% of monoclonal gammopathies [2]. To the best of our 
knowledge, this is the first report of simultaneous prostate 
cancer and multiple myeloma with biclonal gammopathy.
We initially had difficulty in determining the correct di-
agnosis of multiple myeloma in this patient. The diagnosis 
of myeloma requires 1) 10% or more clonal plasma cells on 
bone marrow examination or biopsy-proven plasmacytoma, 
2) presence of serum and/or urinary monoclonal protein 
(except in patients with true nonsecretory multiple myel-
oma), and 3) evidence of end-organ damage (hypercalce-
mia, renal insufficiency, anemia, or bone lesions) related to 
the underlying plasma cell disorder [1]. In this case, bone 
marrow plasma cell distribution was 7.2%, and there was 
no evidence of end organ damage such as anemia, hyper-
calcemia, and renal insufficiency, except for a single L3 ver-
tebral osteolytic plasma cell neoplasm. Furthermore, the 
amount of serum M-protein was very small (217 mg/dL). 
In addition, we performed immunohistochemical staining 
of bone marrow specimens for CD138, kappa, and lambda 
and confirmed positive kappa staining. These findings are 
indicative of bone marrow plasma cell clonality, and there-
fore, we diagnosed the patient with multiple myeloma. 
In many cases, serum electrophoresis produces only a 
single band on the acetate strip, and biclonal gammopathy 
Fig. 5. Bone marrow immunohistochemical staining. (A) CD138 staining. About 7.2% of the marrow nucleated cells showed CD138 immunoreactivity. (B) Kappa 
staining. Positive staining of kappa light chains is shown. (C) Lambda staining. Negative staining of lambda light chains is shown.
Abbreviation: CD, cluster of differentiation. 
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is not recognized until immunoelectrophoresis or immuno-
fixation are done. Studies have shown that the clinical fea-
tures and therapeutic responses of biclonal gammopathy 
were similar to those of monoclonal gammopathy [2, 6]. 
In this case, bone marrow plasma cells showed only posi-
tive kappa staining and urine immunofixation also showed 
a single dark band for kappa antisera. The pathogenesis of 
biclonal gammopathy is unknown, but several potentially 
related environmental factors have been identified. Biclonal 
gammopathy may be due to the proliferation of 2 clones of 
plasma cells, each producing an unrelated monoclonal im-
munoglobulin, or it may result from the production of 2 
monoclonal proteins by a single clone of plasma cells [7]. 
Unfortunately, we did not conduct a FISH or chromosome 
study. If these studies had been performed, more informa-
tion about plasma cell clonality might have been obtained. 
Monoclonal gammopathies occur in approximately 1-3% of 
the normal population [2]. Thus, in the present case, it could 
be possible that the IgA lambda monoclonal protein origina-
ted from another cell clone that was unrelated to myeloma. 
We do not know whether these 2 diseases, multiple my-
eloma and prostate cancer, occurred independently or if 
one disease influenced the development of the other. There 
are only a few reports of multiple myeloma or monoclonal 
gammopathy accompanied by prostate cancer [3, 4, 8, 9]. 
Kao et al. [3] suggested the possible impact of immunosup-
pression from multiple myeloma and chemokines, includ-
ing insulin-like growth factor-1 (IGF-1), interleukin-6 (IL-
6), stromal cell-derived factor-1 (SDF-1), and vascular en-
dothelial growth factor (VEGF), released by circulating my-
eloma cells on the progression of prostate cancer. Kahr et al. 
[8] reported a patient with testicular plasmacytoma after 
chemical castration for prostate cancer. They suggested that 
surgical stress may have exacerbated the clinical course of 
the myeloma, partly because of elevated IL-6 levels after sur-
gery, which would stimulate the growth of myelomas. Kyle 
and Lust [9] have also reported that repeated antigenic sti-
mulation of the reticuloendothelial system, genetic suscep-
tibility for the development of plasma cell dyscrasia in pa-
tients with a positive family history, Epstein-Barr virus in-
fection, lymphoid growth factors (such as IL-6), impairment 
of T-cell function, and lack of suppression of B cells by T cells 
play a role in the development of gammopathy. Most stud-
ies suggested that immune mechanisms may affect the de-
velopment of other malignancies, but none of these mecha-
ni  sms were clearly identified. 
In summary, we report a rare case of multiple myeloma 
with biclonal gammopathy accompanied by prostate cancer. 
In addition to its rarity, this case may provide some insight 
into the pathogenesis of plasma cell disorder and prostate 
cancer. 
Authors’ Disclosures of Potential Conflicts of Interest
No potential conflict of interest relevant to this article was 
reported.
REFERENCES
1. Rajkumar SV. Multiple myeloma: 2011 update on diagnosis, risk-
stratification, and management. Am J Hematol 2011;86:57-65.
2. Kyle RA, Robinson RA, Katzmann JA. The clinical aspects of bi-
clonal gammopathies. Review of 57 cases. Am J Med 1981;71:999-
1008.
3. Kao J, Jani AB, Vijayakumar S. Is there an association between mul-
tiple myeloma and prostate cancer? Med Hypotheses 2004;63:226-
31.
4. Huang E, Teh BS, Saleem A, Butler EB. Recurrence of prostate ad-
enocarcinoma presenting with multiple myeloma simulating skel-
etal metastases of prostate adenocarcinoma. Urology 2002;60:1111.
5. Terris MK, Hausdorff J, Freiha FS. Hematolymphoid malignancies 
diagnosed at the time of radical prostatectomy. J Urol 1997;158: 
1457-9.
6. Knobel D, Zouhair A, Tsang RW, Poortmans P, Belkacémi Y, Bolla 
M, et al. Prognostic factors in solitary plasmacytoma of the bone: 
a multicenter Rare Cancer Network study. BMC Cancer 2006;6:118.
7. Mahto M, Balakrishnan P, Koner BC, Lali P, Mishra TK, Saxena A. 
Rare case of biclonal gammopathy. IJCRI 2011;2:11-4.
8. Kahr WH, Al-Homadhi A, Meharchand J, Bailey DJ, Stewart AK. 
Testicular plasmacytoma following chemical orchiectomy: poten-
tial role of hypogonadism in myeloma proliferation. Leuk Lym-
phoma 1998;28:437-42.
9. Kyle RA and Lust JA. The monoclonal gammopathies (parapro-
teins). Adv Clin Chem 1990;28:145-218.